Literature DB >> 33128684

Uncovering the expression patterns and the clinical significance of miR-182, miR-205, miR-27a and miR-369 in patients with urinary bladder cancer.

Nouha Setti Boubaker1,2, Aymone Gurtner3,4, Nesrine Trabelsi5, Isabella Manni3, Haroun Ayed5,6, Ahmed Saadi5,6, Zeineb Naimi7, Meriem Ksontini8, Mouna Ayadi7, Ahlem Blel8, Soumaya Rammeh8, Mohamed Chebil6, Giulia Piaggio9, Slah Ouerhani5.   

Abstract

BACKGROUND: Given the high recurrence and progression rates and the absence of reliable markers for early detection and prognosis prediction of patients with urothelial bladder cancer (BCa), the exploration of new biomarkers with high specificity is imperative. Mainly, microRNAs (miRNAs), which are involved in the initiation and the progression of BCa. Herein, the expression patterns of miR-182, miR-205, miR-27a and miR-369 were evaluated in patients with urothelial BCa. METHODS AND
RESULTS: The expression levels of the miRNAs were investigated in 90 FFPE tissue samples (23 LG NMIBC, 44 HG NMIBC, 23 MIBC) and 10 non tumoral bladder tissues using TaqMan based RT-qPCR. Data analysis was performed using 2-ΔΔCT method. Correlation to clinical characteristics of the patients was performed using descriptive statistics and the receiver operating characteristic (ROC) curve was performed to evaluate the diagnostic value of all miRNAs. MiR-27a, miR-205 and miR-369 were down-regulated whereas miR-182 was up-regulated in patients compared to controls (p < 0.001). MiR-205 and miR-182 positively segregate between NMIBC and MIBC (p = 0.002 and p = 0.000 respectively) whereas the distribution of miR-27a's expression among these tumor groups was almost significant (p = 0.05) and that of miR-369's expression was irrelevant (p = 0.618). Interestingly, miR-182 was discriminative between LG NMIBC and HG NMIBC (p < 0.001) and Ta/T1 tumors (p = 0.000). Furthermore, high levels of miR-182 were potentially predictive of progression in NMIBC patients (p = 0.01).
CONCLUSION: Collectively, a selection of miRNAs was found to be aberrantly expressed in BCa suggesting a potential diagnostic value in BCa. In addition, the clinical value of miR-182 and miR-205 as potential prognosis biomarkers was highlighted. Indeed, our data provide additional insights into cancer biology. Further functional or target studies are mandatory to strengthen these findings.

Entities:  

Keywords:  Bladder cancer; Diagnosis; Epigenetic; Expression profiles; MicroRNA; Prognosis

Mesh:

Substances:

Year:  2020        PMID: 33128684     DOI: 10.1007/s11033-020-05932-3

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  37 in total

1.  miR-205 targets angiogenesis and EMT concurrently in anaplastic thyroid carcinoma.

Authors:  Haleh Vosgha; Armin Ariana; Robert Anthony Smith; Alfred King-Yin Lam
Journal:  Endocr Relat Cancer       Date:  2018-01-09       Impact factor: 5.678

Review 2.  Urine markers for detection and surveillance of non-muscle-invasive bladder cancer.

Authors:  Derya Tilki; Maximilian Burger; Guido Dalbagni; H Barton Grossman; Oliver W Hakenberg; Juan Palou; Oliver Reich; Morgan Rouprêt; Shahrokh F Shariat; Alexandre R Zlotta
Journal:  Eur Urol       Date:  2011-06-12       Impact factor: 20.096

Review 3.  Circulating cell-free microRNAs as clinical cancer biomarkers.

Authors:  Virginie Armand-Labit; Anne Pradines
Journal:  Biomol Concepts       Date:  2017-05-24

4.  MiR-182 affects renal cancer cell proliferation, apoptosis, and invasion by regulating PI3K/AKT/mTOR signaling pathway.

Authors:  J-H Fu; S Yang; C-J Nan; C-C Zhou; D-Q Lu; S Li; H-Q Mu
Journal:  Eur Rev Med Pharmacol Sci       Date:  2018-01       Impact factor: 3.507

5.  EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.

Authors:  Marko Babjuk; Andreas Böhle; Maximilian Burger; Otakar Capoun; Daniel Cohen; Eva M Compérat; Virginia Hernández; Eero Kaasinen; Joan Palou; Morgan Rouprêt; Bas W G van Rhijn; Shahrokh F Shariat; Viktor Soukup; Richard J Sylvester; Richard Zigeuner
Journal:  Eur Urol       Date:  2016-06-17       Impact factor: 20.096

Review 6.  European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update.

Authors:  Morgan Rouprêt; Marko Babjuk; Eva Compérat; Richard Zigeuner; Richard J Sylvester; Maximilian Burger; Nigel C Cowan; Paolo Gontero; Bas W G Van Rhijn; A Hugh Mostafid; Joan Palou; Shahrokh F Shariat
Journal:  Eur Urol       Date:  2017-09-01       Impact factor: 20.096

7.  miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome.

Authors:  Nadine Ratert; Hellmuth-Alexander Meyer; Monika Jung; Poline Lioudmer; Hans-Joachim Mollenkopf; Ina Wagner; Kurt Miller; Ergin Kilic; Andreas Erbersdobler; Steffen Weikert; Klaus Jung
Journal:  J Mol Diagn       Date:  2013-08-12       Impact factor: 5.568

Review 8.  MicroRNAs as potential biomarkers in cancer: opportunities and challenges.

Authors:  Huiyin Lan; Haiqi Lu; Xian Wang; Hongchuan Jin
Journal:  Biomed Res Int       Date:  2015-03-22       Impact factor: 3.411

9.  MicroRNAs with prognostic significance in bladder cancer: a systematic review and meta-analysis.

Authors:  Yongpeng Xie; Xin Ma; Luyao Chen; Hongzhao Li; Liangyou Gu; Yu Gao; Yu Zhang; Xintao Li; Yang Fan; Jianwen Chen; Xu Zhang
Journal:  Sci Rep       Date:  2017-07-17       Impact factor: 4.379

10.  Urine gamma-synuclein as a biomarker for the diagnosis of bladder cancer.

Authors:  Caiyun Liu; Bingbing Shi; Chonghua Hao; Qinghai Wang; Qiang Lv; Nianzeng Xing; Jianzhong Shou; Like Qu; Yanning Gao; Chao Qin; Jiyu Zhao; Chengchao Shou
Journal:  Oncotarget       Date:  2016-07-12
View more
  1 in total

1.  Comprehensive Analysis of Correlations in the Expression of miRNA Genes and Immune Checkpoint Genes in Bladder Cancer Cells.

Authors:  Przemysław A Stempor; Dror Avni; Raya Leibowitz; Yechezkel Sidi; Maria Stępień; Tomasz Dzieciątkowski; Paula Dobosz
Journal:  Int J Mol Sci       Date:  2021-03-04       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.